15 reports

Exposure to particle pollution causes a number of health problems, including respiratory illnesses (such as asthma and bronchitis) and CVD.

  • Eyewear
  • Asia
  • Israel
  • Market Size
  • Medtronic, Inc.

Asthma is the fourth-most prevalent chronic disease in medical scheme beneficiaries.

  • Eyewear
  • Africa
  • South Africa
  • Market Size
  • Roche Group

It is estimated that the annual rate of increase in the prevalence of asthma is ##. ##% and the cost per patient is SAR##, ## ($##, ##) per year.

  • Eyewear
  • Asia
  • Saudi Arabia
  • Market Size
  • Pfizer Inc.

asthma, nasal polyposis and eosinophilic oesophagitis; and VaxiGrip QIV IM, a quadrivalent inactivated influenza vaccine.

  • Eyewear
  • Asia
  • Turkey
  • Market Size
  • Baxter International Inc.

In 2010, asthma and diabetes were the other major diseases affecting the UK, with prevalence of approximately ##. ## million for asthma, and ##. ## million for diabetes.

  • Eyewear
  • Europe
  • United Kingdom
  • Market Size
  • Merck & Co., Inc.
  • Eyewear
  • Asia
  • South Korea
  • Market Size
  • Baxter International Inc.

Increases in PM## cause respiratory diseases such as asthma and COPD.

  • Eyewear
  • Asia
  • India
  • Market Size
  • Cipla Ltd

The company has candidates for multiple disease conditions in the pipeline, including asthma, allergy, atherosclerosis, cancer, diabetes, heart disease, hypertension, infectious diseases, inflammatory diseases, migraine, neurodegenerative diseases, ophthalmic diseases, osteoporosis, psychia

  • Eyewear
  • United States
  • Market Size
  • Johnson & Johnson
  • Medtronic, Inc.

ASTHMA.

  • Eyewear
  • World
  • Company
  • Deals & Alliance
  • Abbott Laboratories, Inc.

Clinical studies that started at the beginning of the year with the asthma product Ventica®continue in Croatia, Germany, and Finland.

  • Clinical Trial
  • Eyewear
  • Ophthalmology
  • United States
  • GlobalData's company

The FDA approved an expanded age range for Xolair (omalizumab) to include children six to ## years of age with moderate to severe persistent asthma.

  • Clinical Trial
  • Eye Disease
  • Eyewear
  • Ophthalmology
  • GlobalData's company

The pivotal Phase ## LIBERTY ASTHMA QUEST study of dupilumab for the treatment of asthma completed enrollment during the third quarter of 2016.

  • Eye Disease
  • Eyewear
  • North America
  • United States
  • Alcon, Inc.

The FDA approved an expanded age range for Xolair (omalizumab) to include children six to ## years of age with moderate to severe persistent asthma.

  • Eyewear
  • Medical Device
  • United States
  • Company
  • GlobalData's company

Sandoz Generic Advair Diskus®regulatory submission was accepted by FDA for treatment of asthma and airflow obstruction and reducing exacerbations in patients with COPD.

  • Eyewear
  • Medical Device
  • United States
  • Company
  • GlobalData's company

The results of a Phase II trial of QAW## (fevipiprant), published in Lancet Respiratory Medicine, showed fevipiprant significantly decreases sputum eosinophils compared to placebo in patients with severe asthma.

  • Eyewear
  • Medical Device
  • United States
  • Company
  • GlobalData's company